Stocksigma LogoStocksigma Logo

Jagsonpal Pharmaceuticals Reports Q2 Results and Strategic Acquisitions

Jagsonpal Pharmaceuticals reported standalone Q2 revenue from operations of ₹813.75m, up 9.28% YoY from ₹744.65m, with net profit rising slightly to

Jagsonpal Pharmaceuticals Reports Q2 Results and Strategic Acquisitions

Jagsonpal Pharmaceuticals Ltd · Outcome · 28 Oct 2026, 11:43 pm

Jagsonpal Pharmaceuticals Reports Q2 Results and Strategic Acquisitions Jagsonpal Pharmaceuticals reported standalone Q2 revenue from operations of ₹813.75m, up 9.28% YoY from ₹744.65m, with net profit rising slightly to ₹125.90m from ₹125.74m. For H1 ended 30th Sep'26, standalone revenue stood at ₹1,636.07m with net profit at ₹257.79m. Consolidated Q2 revenue reached ₹963.71m and net profit was ₹122.87m, reflecting the consolidation of newly acquired 85% stake in Aequitas Healthcare for ₹208m effective 1st Jul'26. Additionally, the company signed a BTA on 23rd Sep'26 to acquire Group Pharmaceuticals' Wellness Portfolio.

Original exchange filing (PDF)

More announcements from Jagsonpal Pharmaceuticals Ltd

All Jagsonpal Pharmaceuticals Ltd announcements